Acute Pudendal Nerve Stimulation On Leak Point Pressure In Women Urodynamic Early Feasibility Study

Urinary Incontinence Clinical Trial

— PNS_UDT  

Official title:

The Effect Of Acute Pudendal Nerve Stimulation On Leak Point Pressure In Women Urodynamic: Early Feasibility Study

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT05128682
• Other study ID #: 2021-286
• Status: Terminated
• Phase: N/A
• Start date: May 24, 2022
• Est. completion date: September 7, 2022

Study information

• Verified date: May 2023
• Source: William Beaumont Hospitals
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is tp evaluate the changes in stress induced Urethral Leak Point Pressures (LPP) and other urodynamic measurements in response to acute pudendal nerve stimulation (PNS) in patients with a pre-existing implanted urological neurostimulator stimulating the pudendal nerve.

Description:

Patients with a neurostimulator implanted at the pudendal nerve will be enrolled and undergo urodynamic testing. Before testing, study staff will provide an oral antibiotic (to reduce the risk of infection) and adjust the stimulation settings with a goal to increase urethral pressure from baseline by at lest 20cm H2O, without causing the patient discomfort/distress. These settings will be used throughout urodynamics. Before filling the bladder, a urethral pressure profile study will be completed 3 times with stimulation off, then 3 times with stimulation on. Leak point pressure (LPP) testing will then be completed. The patient's bladder will be filled following standard urodynamic testing protocol. Filling will be paused every 50-100mL to complete LPP assessment. Subjects will be asked to complete a light cough, medium cough, forceful cough, and Valsalva maneuver (in that order). Detrusor pressure will be measured at each event, and staff will document whether or not a leak was elicited. This will be completed with stimulation off, then with stimulation on, as the bladder is filled. Once the subject reports a strong urge to void, urethral pressure profile assessment will be completed again: 3 times with stimulation off, then 3 times with stimulation on. Once urodynamic testing is complete and the patient's bladder is emptied, a measurement of urethral pressure will be completed with stimulation off, then during 5 seconds of stimulation, then again with stimulation off.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 4
• Est. completion date: September 7, 2022
• Est. primary completion date: July 27, 2022
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 18 Years to 85 Years

Eligibility

Inclusion Criteria:

• Women between the ages of 18 and 85 years old, inclusive.

• Implanted with a neurostimulation device for at least 3 months prior to consent (Medtronic Interstim neurostimulator models 3023, 3058, 97810, or similar).

• Implanted with a tined lead that is placed and functionable at the pudendal nerve (Medtronic model 3889 or similar).

• Is capable of understanding clinical study procedures and giving informed consent.

• Willing and able to visit the clinic for the UDT evaluation (study procedure)

Exclusion Criteria:

• Medically unstable at time of study and unsafe to undergo urodynamic testing as determined by the investigator.

• History of bladder cancer.

• History of pelvic radiotherapy.

• Active gross hematuria.

• Active symptomatic urinary tract infection (UTI)

• Active symptomatic uncontrolled bladder instability as determined by the investigator.

• History or symptoms of cystocele, enterocele, or rectocele of grade 3 or 4. Per the medical record or as determined by the investigator.

• Presence of an artificial urinary sphincter.

• Women who are pregnant and/or have given birth in the previous 12 months

• Any medical condition that would interfere with the patient's ability to comply with the protocol and/or may affect the outcome of this study or safety of the subject as determined by the investigator

• BMI greater than 39.

Related Conditions & MeSH terms

• Enuresis
• Urinary Incontinence

Intervention

Diagnostic Test:
• Urodynamic testing with and without pudendal nerve stimulation
A urodynamic test (UDT) for eligible subjects with and without acute PNS will be conducted. Prior to introducing the acute PNS, the subject's original stimulation properties will be turned off. The implanted neurostimulator device will be programmed to deliver acute PNS per individual tolerance level with the objective of increasing external urethral sphincter pressure. The LPP during Valsalva maneuver or forceful coughing will be assessed with and without acute PNS. The LPP will be assessed at increasing bladder volumes until major detrusor instability, significant leakage (more than drops, stream) or subject discomfort (strong desire to void) is observed. Finally, a UPP with PNS set in an on/off cycling regimen will be conducted to observe the effect on pressures along the length of the urethra.

Locations

Country	Name	City	State
United States	Beaumont Hospital - Royal Oak	Royal Oak	Michigan
United States	Beaumont Hospital Royal Oak	Royal Oak	Michigan

Sponsors (1)

Lead Sponsor	Collaborator
William Beaumont Hospitals

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Pulse Amplitude Triggering Patient Sensation at First Verbally Reported Sensation.	PNS final settings including: pulse amplitude, measured in mA, when subject first verbalizes sensation. Pulse amplitude is the amplitude of the electric pulses; measured in Milliamps (mA). This is a setting present on the neuromodulation device, it is not calculated.	After Visit 2 activities are complete. An average of 30 days after enrollment.
Primary	Pulse Frequency Triggering Patient Sensation at First Verbally Reported Sensation.	PNS final settings including: pulse frequencies, measured in Hz, when subject first verbalizes sensation.	After Visit 2 activities are complete. An average of 30 days after enrollment.
Primary	Pulse Width Triggering Patient Sensation at First Verbally Reported Sensation.	PNS final settings including: pulse widths, measured in µs, when the subject first verbalizes sensation.	After Visit 2 activities are complete. An average of 30 days after enrollment.
Primary	Identification of All Study-related Adverse Events	Safety and tolerability will be assessed in relation to the incidence of study related adverse events reported.	After Visit 2 activities are complete. An average of 30 days after enrollment.
Primary	Changes in Leak Point Pressure (LPP) Upon Acute PNS	Measurement of the change in LPP with acute PNS compared to without stimulation. To assess LPP, the urethral pressure increase will be calculated by subtracted pressure with and without stimulation at the "final setting". In cm water.	After Visit 2 activities are complete. An average of 30 days after enrollment.
Secondary	Effect of Acute PNS on the Urethral Pressure Profile (UPP).	Measure the maximum urethral closure pressure with and without programmed pudendal nerve stimulation. In cm water.; Urethral pressure profile is a test of the bladder neck, urethra, and urethral sphincters that is completed with urodynamic equipment. A small catheter is pulled at a constant rate from the bladder neck down the urethra to provide the functional length of the urethra and points of maximal urethral resistance at the urethral sphincter. It is a procedure used to measure the competency of the urethral sphincter (outflow resistance).	After Visit 2 activities are complete. An average of 30 days after enrollment.
Secondary	Effect of Acute PNS on Max Cystometic Capacity.	Max cystometic capacity will be collected, with and without programmed PNS, the difference will be reported. In mL.	After Visit 2 activities are complete. An average of 30 days after enrollment.
Secondary	Effect of Acute PNS on Post Void Residual.	Post void residual collected at end of UDT testing. Measured in mL.	After Visit 2 activities are complete. An average of 30 days after enrollment.